Slow-release apomorphine patch just passed first blinded review, and company says the early numbers already look like what it hoped for.
There’s a moment in advanced Parkinson’s disease that doctors call “OFF” time. It’s when the pills stop working mid-cycle, and a person who was walking and talking normally an hour ago suddenly can’t get out of a chair. It happens unpredictably, sometimes several times a day, and it’s one of the cruelest parts of a disease that already takes so much.
Serina Therapeutics thinks it has a way to smooth that out. On 9 September, the Huntsville, Alabama-based biotech announced that an independent safety panel had finished reviewing the first group of patients in its Phase 1b study of SER-252, a long-acting, under-the-skin version of apomorphine, and cleared the trial to move to the next, higher dose [1].
For a longevity-minded reader, this is what matters most: Parkinson’s isn’t just a disease of old age; it’s one of the clearest examples of how aging steals functional independence long before it ends a life. A drug that keeps someone mobile and predictable through their 70s and 80s isn’t adding years so much as protecting the years already there. That’s the whole point of extending healthspan, not just lifespan.
Apomorphine itself isn’t new. It’s a well-established dopamine therapy that’s been used for decades to rescue patients during OFF episodes, usually through injections or infusion pumps. The problem has always been delivery: existing methods are either short-lived or come with a heavy treatment burden. Serina’s pitch is that its POZ Platform, a drug-optimization technology the company has built its entire pipeline around, can turn apomorphine into a steadier, background therapy rather than a rescue shot.
Eight patients made up Cohort 1, randomized three-to-one between SER-252 and placebo in a study designed to be double-blind and placebo-controlled throughout. Because the researchers wanted a clean read on the drug’s own effects, patients were temporarily taken off their usual Parkinson’s medications during this phase, which let the team isolate what SER-252 alone was doing to both blood levels of the drug and to patients’ motor symptoms.
What they saw, at the lowest dose tested, was a pharmacokinetic profile consistent with sustained, long-lasting apomorphine exposure, plus what the company describes as sustained periods of improved motor function in individual patients on exploratory clinical measures. Those are still blinded, exploratory observations from a small group, not proof of efficacy. However, they were enough for the Safety Monitoring Committee to recommend advancing to Cohort 2, a higher dose.
“These initial observations strengthen our confidence in SER-252 and are consistent with the profile the program was designed to achieve,” said Steve Ledger, Serina’s CEO. “At the lowest dose evaluated, we observed the sustained pharmacokinetic profile SER-252 was engineered to achieve, together with encouraging clinical observations in a study designed to provide an assessment of treatment effect.”
He added that the safety committee’s green light, “giving us a clear path into Cohort 2 while preserving the integrity of the blinded study,” was just as important as the pharmacokinetic data itself, since keeping the study blind protects the credibility of whatever results come next.
The full study, called SER-252-1b, is a bigger undertaking than Cohort 1 alone suggests. It’s designed to run five single-dose cohorts (40 patients total) followed by up to three multiple-dose cohorts (48 more), across trial sites in the US, Australia, South Korea and Taiwan. Serina says topline data from the single-dose portion should be ready in the first half of 2027.
There’s still a long road between a cleared safety review and an approved medicine, and the company is careful to frame these findings as preliminary and blinded. Nonetheless, if continuous dopaminergic stimulation delivered this way can reduce the dyskinesia and unpredictability that come with existing infusion therapies, it could give a genuinely underserved group of older patients something that’s been in short supply: a treatment option that doesn’t feel like a trade-off between mobility now and burden later.
